Jeffrey L. Ives - 17 Aug 2023 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Director
Signature
/s/ Derek Meisner, Attorney-in-Fact
Issuer symbol
ABOS
Transactions as of
17 Aug 2023
Net transactions value
-$240,814
Form type
4
Filing time
18 Aug 2023, 18:31:27 UTC
Previous filing
07 Jun 2023
Next filing
06 Jun 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Options Exercise $28,187 +39,149 $0.7200* 39,149 17 Aug 2023 Direct
transaction ABOS Common Stock Sale $253,686 -39,149 -100% $6.48 0 17 Aug 2023 Direct F1
transaction ABOS Common Stock Options Exercise $3,332 +2,800 $1.19* 2,800 17 Aug 2023 Direct
transaction ABOS Common Stock Sale $18,648 -2,800 -100% $6.66 0 17 Aug 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Stock Option (right to buy) Options Exercise $0 -39,149 -100% $0.000000* 0 17 Aug 2023 Common Stock 39,149 $0.7200 Direct F2
transaction ABOS Stock Option (right to buy) Options Exercise $0 -2,800 -100% $0.000000* 0 17 Aug 2023 Common Stock 2,800 $1.19 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on May 17, 2023.
F2 The option is fully vested.